Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11482499 | 0.68 | MEN1 (0.45) | GAALMNAMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL2436901 | 0.64 | OPRL1 (0.42) | OPRM1OPRK1 | |
| SCHEMBL11331123 | 0.64 | FAAH (0.35) | GAAMAPK1 | |
| SCHEMBL10769617 | 0.63 | OPRL1 (0.45) | OPRM1OPRD1OPRK1 | |
| SCHEMBL10769619 | 0.63 | OPRL1 (0.45) | OPRM1OPRD1OPRK1 | |
| SCHEMBL10769625 | 0.63 | OPRL1 (0.45) | OPRM1OPRD1OPRK1 | |
| SCHEMBL9510310 | 0.63 | GAA (0.31) | GAAMAPK1 | |
| SCHEMBL14879904 | 0.62 | CYP19A1 (0.40) | GAAMAPK1 | |
| SCHEMBL23261408 | 0.61 | GAA (0.38) | GAALMNAMAPTCES2MAPK1 | |
| SCHEMBL11244880 | 0.60 | LMNA (0.35) | GAALMNAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2852598-B3 | RING CONSTRAINED ANALOGS AS ARGINASE INHIBITORS | MARS INC (US) | 2016-10-19 | — | — | EP | disclosed |
| EP-2852598-B1 | RING CONSTRAINED ANALOGS AS ARGINASE INHIBITORS | MARS INC (US) | 2016-05-11 | — | — | EP | disclosed |
| US-9200011-B2 | Ring constrained analogs as arginase inhibitors | MARS, INCORPORATED (US) | 2015-12-01 | — | — | US | disclosed |
| EP-2852598-A1 | RING CONSTRAINED ANALOGS AS ARGINASE INHIBITORS | Mars, Incorporated (US) | 2015-04-01 | — | — | EP | disclosed |
| US-20150080341-A1 | RING CONSTRAINED ANALOGS AS ARGINASE INHIBITORS | MARS, INCORPORATED | 2015-03-19 | — | — | US | disclosed |
| WO-2013158262-A1 | RING CONSTRAINED ANALOGS AS ARGINASE INHIBITORS | MARS, INCORPORATED (US) | 2013-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080341-A1 | RING CONSTRAINED ANALOGS AS ARGINASE INHIBITORS | ARG1, ARG2, PADI1 | GAA 126/4885LMNA 3660/4885MAPT 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.